These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

895 related articles for article (PubMed ID: 12833138)

  • 1. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells.
    Song L; Turkson J; Karras JG; Jove R; Haura EB
    Oncogene; 2003 Jul; 22(27):4150-65. PubMed ID: 12833138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells.
    Garcia R; Yu CL; Hudnall A; Catlett R; Nelson KL; Smithgall T; Fujita DJ; Ethier SP; Jove R
    Cell Growth Differ; 1997 Dec; 8(12):1267-76. PubMed ID: 9419415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer.
    Dalwadi H; Krysan K; Heuze-Vourc'h N; Dohadwala M; Elashoff D; Sharma S; Cacalano N; Lichtenstein A; Dubinett S
    Clin Cancer Res; 2005 Nov; 11(21):7674-82. PubMed ID: 16278387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Grb2 regulates Stat3 activation negatively in epidermal growth factor signalling.
    Zhang T; Ma J; Cao X
    Biochem J; 2003 Dec; 376(Pt 2):457-64. PubMed ID: 14498832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of Stat3 preassembled with platelet-derived growth factor beta receptors requires Src kinase activity.
    Wang YZ; Wharton W; Garcia R; Kraker A; Jove R; Pledger WJ
    Oncogene; 2000 Apr; 19(17):2075-85. PubMed ID: 10815799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth.
    Niu G; Bowman T; Huang M; Shivers S; Reintgen D; Daud A; Chang A; Kraker A; Jove R; Yu H
    Oncogene; 2002 Oct; 21(46):7001-10. PubMed ID: 12370822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of hepatic acute phase gene expression by epidermal growth factor and Src protein tyrosine kinases in murine and human hepatic cells.
    Wang Y; Ripperger J; Fey GH; Samols D; Kordula T; Wetzler M; Van Etten RA; Baumann H
    Hepatology; 1999 Sep; 30(3):682-97. PubMed ID: 10462375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis.
    Niu G; Wright KL; Huang M; Song L; Haura E; Turkson J; Zhang S; Wang T; Sinibaldi D; Coppola D; Heller R; Ellis LM; Karras J; Bromberg J; Pardoll D; Jove R; Yu H
    Oncogene; 2002 Mar; 21(13):2000-8. PubMed ID: 11960372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGF-dependent and independent programmed cell death pathways in NCI-H596 nonsmall cell lung cancer cells.
    Lei W; Mayotte JE; Levitt ML
    Biochem Biophys Res Commun; 1998 Apr; 245(3):939-45. PubMed ID: 9588219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells.
    Mora LB; Buettner R; Seigne J; Diaz J; Ahmad N; Garcia R; Bowman T; Falcone R; Fairclough R; Cantor A; Muro-Cacho C; Livingston S; Karras J; Pow-Sang J; Jove R
    Cancer Res; 2002 Nov; 62(22):6659-66. PubMed ID: 12438264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of IL-6 signaling by p53: STAT3- and STAT5-masking in p53-Val135-containing human hepatoma Hep3B cell lines.
    Rayanade RJ; Ndubuisi MI; Etlinger JD; Sehgal PB
    J Immunol; 1998 Jul; 161(1):325-34. PubMed ID: 9647240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells.
    Real PJ; Sierra A; De Juan A; Segovia JC; Lopez-Vega JM; Fernandez-Luna JL
    Oncogene; 2002 Oct; 21(50):7611-8. PubMed ID: 12400004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of epidermal growth factor receptor and STAT-3 activation in autonomous proliferation of SUM-102PT human breast cancer cells.
    Sartor CI; Dziubinski ML; Yu CL; Jove R; Ethier SP
    Cancer Res; 1997 Mar; 57(5):978-87. PubMed ID: 9041204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention.
    Buettner R; Mora LB; Jove R
    Clin Cancer Res; 2002 Apr; 8(4):945-54. PubMed ID: 11948098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.
    Maulik G; Kijima T; Ma PC; Ghosh SK; Lin J; Shapiro GI; Schaefer E; Tibaldi E; Johnson BE; Salgia R
    Clin Cancer Res; 2002 Feb; 8(2):620-7. PubMed ID: 11839685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation.
    Luppi F; Longo AM; de Boer WI; Rabe KF; Hiemstra PS
    Lung Cancer; 2007 Apr; 56(1):25-33. PubMed ID: 17175059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of STATs in transcriptional control and their impact on cellular function.
    Bromberg J; Darnell JE
    Oncogene; 2000 May; 19(21):2468-73. PubMed ID: 10851045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. STAT3 induces anti-hepatitis C viral activity in liver cells.
    Zhu H; Shang X; Terada N; Liu C
    Biochem Biophys Res Commun; 2004 Nov; 324(2):518-28. PubMed ID: 15474458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor.
    Alvarez JV; Greulich H; Sellers WR; Meyerson M; Frank DA
    Cancer Res; 2006 Mar; 66(6):3162-8. PubMed ID: 16540667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of pp60c-Src reduces Bcl-XL expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors.
    Karni R; Jove R; Levitzki A
    Oncogene; 1999 Aug; 18(33):4654-62. PubMed ID: 10467412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.